Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle

Executive Summary

King Pharmaceuticals believes the FDA review of its abuse-resistant painkiller Embeda is "substantially complete," and that the company will be able to launch the drug in 2009, CEO Brian Markison assured investors during an earnings call Feb. 26

You may also be interested in...



FDA Class-Wide REMS Meeting Won’t Deter Embeda Approval, King Believes

Drug maker expects to meet with FDA in July on “complete response” for Remoxy.

Record-Setting REMS: FDA’s Classwide Opioid Program Will Be “Massive”

FDA is starting the process of developing a classwide Risk Evaluation & Mitigation Strategy for potent opioid drug products - with the resulting program expected to be the most extensive REMS required by the agency since the implementation of the FDA Amendments Act

Opioid Approval Delay? Class REMS Poses Legal Questions For Pending Drugs

FDA approvability decisions on pending extended-release opioids will be contingent on the resolution of legal questions related to the agency's Risk Evaluation and Mitigation Strategy authorities under the FDA Amendments Act, Office of New Drug Director John Jenkins said

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel